Seagen signs $700m licensing deal with LAVA for solid tumours drug candidate
As per the terms of the agreement, Seagen will be granted an exclusive worldwide license for LAVA-1223 by…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Sep 22
As per the terms of the agreement, Seagen will be granted an exclusive worldwide license for LAVA-1223 by…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Sep 22
The EC approval follows a positive opinion granted by the European Medicines Agency (EMA)’s Committee for Medicinal Products…
26 Sep 22
The US District Court found both Merck patents regarding sitagliptin to be valid and infringed
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Sep 22
GSK will obtain exclusive rights to develop and market Tebipenem HBr worldwide, excluding Japan and certain other Asian…
23 Sep 22
The patient dosing with the haemophilia A gene therapy candidate is expected to start in October 2022 in…
22 Sep 22
Retevmo is an oral, selective RET kinase inhibitor, indicated for locally advanced or metastatic solid tumours with a…
21 Sep 22
The transaction, which has been unanimously approved by the boards of directors of both the companies, is expected…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 22
Pfizer has used CytoReason's biological models in its research to improve the understanding of the immune system and…
20 Sep 22
The EC approval of Vabysmo is supported by positive results from four Phase 3 studies, including TENAYA and…
20 Sep 22
Through the deal, GENFIT will gain access to VS-01, a liposomal-based drug candidate for the treatment of acute-on-chronic…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates